From WAC to 340B Ceiling Price: Understanding the 340B Rebate Pilot
By Mandy Mori,
Senior Manager, Health Care Consulting Practice, Moss Adams (now Baker Tilly)
By Jesse Vo,
Senior Manager, Provider Reimbursement Services, Moss Adams (now Baker Tilly)
The way discounts are handled for nine high-impact drugs will change under the voluntary 340B Rebate Model Pilot program launched by the Health Resources and Services Administration (HRSA). The pilot requires covered entities to purchase these drugs at the wholesale acquisition cost (WAC) and then receive a post-purchase rebate to achieve the 340B ceiling price.
Under the current 340B model, covered entities qualify for the program, set up a 340B account with a wholesaler, and purchase drugs at the discounted 340B price up front. The pilot, scheduled to begin January 1, 2026, represents a significant structural change that will affect operations, billing, compliance, and cash flow—making it essential to prepare now.
Read article
Health Plan Financial Reports for California and Washington State
By David PeelPublisher and Editor, Healthcare News
We recently updated our financial reporting for health plans in California and Washington State. Click on the links below to see the numbers.